Webb10 feb. 2024 · SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, … Webb10 feb. 2024 · Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key se
Sydnexis Inc.
Webb29 mars 2024 · SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q4 2024 Earnings Conference Call March 29, 2024 8:30 AM ETCompany ParticipantsDebbie Etchison - Executive Director, CommunicationsMarco Taglietti -... Webb31 mars 2024 · SCYNEXIS announced U.S. Food and Drug Administration (FDA) approval of a supplemental NDA for a second indication for BREXAFEMME for the reduction in incidence of recurrent vulvovaginal candidiasis (RVVC). The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2024. eli whitney gun factory
SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study …
Webb15 feb. 2024 · Scynexis has announced positive results from its global Phase 3 CANDLE study investigating the efficacy and safety of oral ibrexafungerp (Brexafemme) for the prevention of recurrent vulvovaginal candidiasis (VVC), or yeast infection, a condition that causes a considerable amount of discomfort for patients, defined as 3 or more episodes … Webb14 juli 2024 · JERSEY CITY, N.J., July 14, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to … Webb11 maj 2024 · Earlier this year, Scynexis also announced positive results from its global Phase III CANDLE study investigating the safety and efficacy of oral ibrexafungerp for … eli whitney invention 1793